Table 1 Demographics of patients before initiation of topical tacrolimus
From: Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases
Cases, Eyes | 12, 24 |
Sex, n (%) | |
Male/Female | 10 (83.3)/2 (16.7) |
Age (y) ± SD | 15.7 ± 8.5 |
Duration of disease (y) ± SD | 4.3 ± 1.8 |
Type of allergic conjunctival diseases, n (%) | |
Atopic Keratoconjunctivitis (AKC) | 7 (58.3) |
Male / Female | 6 (86) / 1 (14) |
Age (y) ± SD | 17.9 ± 10.4 |
Period of onset (y) ± SD | 9.7 ± 3.0 |
Vernal Keratoconjunctivitis (VKC) | 5 (41.7) |
Male / Female | 4 (80) / 1 (20) |
Age (y) ± SD | 14.0 ± 5.9 |
Period of onset (y) ± SD | 6.4 ± 0.7 |
Other allergic complications, n (%) | |
Asthma | 2 (16.7) |
Rhinitis | 6 (5.0) |
Atopic dermatitis (AD) | 12 (100) |
Pretreatment, eyes (%) | |
Topical antihistamine and/or mast cell stabilizer | 20 (83.3) |
0.1% fluorometholone (FLM) | 20 (83.3) |
0.1% betamethasone (BEM) | 4 (16.7) |
Topical NSAIDs | 4 (16.7) |
Topical cyclosporine | 10 (41.7) |
Tacrolimus ointment | 2 (8.3) |
Oral steroid | 2 (8.3) |